- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06345963
Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Schizophrenia is a severe mental illness that affects about 1% of the population but a major source of disability. Information processing between brain regions occurs due to transfer of electrical impulses among them. This process is determined by the existing neuronal/fiber connections, which may be altered and or modified in the presence of neuronal stimulation or cognitive intervention. The frontal lobe information flow is critical for higher cognitive functions, thought processes, and proper emotional and behavioral responses. Improving the myelination in the frontal lobe may increase cognitive functions and reduce risks to develop symptoms of schizophrenia. The investigators propose that increasing electrical signaling in the frontal white matter in patients with schizophrenia may also enhance myelination and improve the white matter integrity.
The patients with schizophrenia will receive active repetitive transcranial magnetic stimulation (rTMS) treatment. The rTMS with H coil is FDA-cleared for short-term smoking cessation in the general population. Its efficacy in myelination modulation has not been evaluated.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Xiaoming Du, PhD
- Phone Number: 443-882-9717
- Email: Xiaoming.Du@uth.tmc.edu
Study Contact Backup
- Name: Victoria M Acosta
- Phone Number: 713-486-2740
- Email: Victoria.Acosta@uth.tmc.edu
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77054
- The University of Texas Health Science Center, Houston
-
Contact:
- Victoria Acosta
- Phone Number: 713-486-2740
- Email: Victoria.Acosta@uth.tmc.edu
-
Contact:
- Xiaoming Du, PhD
- Phone Number: 410-402-6036
- Email: Xiaoming.Du@uth.tmc.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male and female ages between ages 18-60 years
- Ability to give written informed consent (age 18 or above)
- Diagnosed with schizophrenia-spectrum disorder and Evaluation to Sign Consent (ESC) above 10.
Exclusion Criteria:
- Inability to sign informed consent.
- Any history of seizures.
- Any acute and unstable major medical illnesses that may affect normal brain functioning. Examples of these conditions include, but not limited to, recent stroke, seizure, history of significant head trauma, CNS infection or tumor, other significant brain neurological conditions (As this is a study of medical comorbidity, most medical conditions, once stable, are not exclusion criteria).
- Taking > 400 mg clozapine/day.
- Failed TMS screening questionnaire.
- Significant alcohol or other drug use (substance dependence within 6 months or substance abuse within 1 month) other than nicotine or marijuana dependence.
- A history of thrombosis, family history of thrombosis, or medical conditions that may lead to a hypercoagulable state (increased chance to develop blood clots)
- Woman who is pregnant (child-bearing potential but not on contraceptive and missing menstrual period; or by self-report; or by positive urine pregnancy test).
- History of head injury with loss of consciousness over 10 minutes; history of brain surgery
- Cannot refrain from using alcohol and/or marijuana 24 hours or more prior to experiments.
- Students and employees currently involved with our lab (lab employees and personnel will be excluded from the study to avoid possible coercion or possible appearance of coercion, or chance of breach of privacy and confidentiality).
- For MRI, unable to undergo MRI scanning due to metallic devices or objects (cardiac pacemaker or neurostimulator, some artificial joints, metal pins, surgical clips, or other implanted metal parts) or claustrophobic to the scanner.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active rTMS
Participants in this group will receive active H-coil delivered rTMS.
|
Multiple trains of rTMS in a day, for multiple days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
brain microstructural integrity from magnetic resonance imaging (MRI)
Time Frame: 2 weeks
|
The change of brain microstructural integrity from MRI scan will be used to represent the TMS effects on white matter.
|
2 weeks
|
Resting-state functional connectivity (rsFC) from functional MRI
Time Frame: 2 weeks
|
The change of rsFC will be used to represent the TMS effects on brain connectivity.
|
2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Electrophysiological responses measured by mismatch negativity and steady-state auditory evoked potentials from electroencephalography recording (EEG)
Time Frame: 2 weeks
|
The change of EEG signals represents the TMS effects on electrophysiological responses.
|
2 weeks
|
Cognitive insight, depression, perception, and delusion measured from questionnaires
Time Frame: 2 weeks
|
The change of outcomes of those questionnaires represents the TMS effects on various symptoms of schizophrenia.
|
2 weeks
|
Cognitive functions measured by the MATRICS consensus cognitive battery (MCCB)
Time Frame: 2 weeks
|
The changes of MCCB outcomes represents the TMS effects on cognitive functions of patients.
|
2 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Xiaoming Du, PhD, The University of Texas Health Science Center, Houston
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HSC-MS-23-1044
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
-
NYU Langone HealthNot yet recruitingTreatment-resistant SchizophreniaUnited States
-
Johns Hopkins UniversityNational Institute of Mental Health (NIMH)RecruitingTreatment-resistant SchizophreniaUnited States
Clinical Trials on active H-coil delivered rTMS
-
The University of Texas Health Science Center,...RecruitingSmoking Cessation | Schizophrenia | Nicotine AddictionUnited States
-
Giancarlo ComiCompletedAlzheimer DiseaseItaly
-
Centre for Addiction and Mental HealthBrainswayCompleted
-
Giancarlo ComiCompleted
-
Universitaire Ziekenhuizen KU LeuvenCompletedEpilepsies, PartialBelgium
-
New York State Psychiatric InstituteCity University of New York, School of Public HealthWithdrawnDepersonalization DisorderUnited States
-
Nadine ATTALRecruitingFibromyalgia | Neuropathic PainFrance
-
University Health Network, TorontoUnknown
-
University Health Network, TorontoTerminatedAnorexia Nervosa | Bulimia NervosaCanada
-
Hadassah Medical OrganizationCompletedPost Traumatic Stress DisorderIsrael